TRPV2-induced Ca2+-calcineurin-NFAT signaling regulates differentiation of osteoclast in multiple myeloma
Open Access
- 16 October 2018
- journal article
- research article
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 16 (1) , 68
Abstract
Myeloma bone disease (MBD) can cause bone destruction and increase the level of Ca2+ concentration in the bone marrow microenvironment by stimulating osteoclastic differentiation. Nevertheless, the relationships between MBD and highly efficient stimuli of Ca2+ in multiple myeloma (MM) progression, and possible regulatory mechanisms are poorly defined. Here, we reported that the nonselective cation channel transient receptor potential vanilloid 2 (TRPV2) plays a functional role in Ca2+ oscillations and osteoclastogenesis. To investigate the expression of TRPV2 in MM, we analyzed publicly available MM data sets and performed immunohistochemistry in MM patients. The correlations between TRPV2 expression levels and osteoclast-related cytokines were analyzed. Fluo-4 staining and ELISA assays were used to assess the regulated function of TRPV2 in intracellular Ca2+ and cytokines. Western blotting and Chromatin immunoprecipitation (ChIP) assays were performed to explore the signaling pathway of TRPV2-induced osteoclastic differentiation. Real-time PCR, Western blotting, ELISA and tartrate-resistant acid phosphatase (TRAP) staining were performed to detect the biological effects of TRPV2 inhibitor on osteoclastogenesis. The functional expression of TRPV2, involved in the osteolysis through gating the calcium influx, was changed in the MM cells cultured in a high Ca2+ environment. Mechanistically, TRPV2 modulates nuclear factor-κB ligand (RANKL)-dependent osteoclastic differentiation through the Ca2+-calcineurin-NFAT signaling pathway. Of clinical relevance, systemic administration with SKF96365 could attenuate the MM-induced osteoclast formation in vitro. Our study uncovers the possible roles of TRPV2, which enhances MBD, suggesting that targeting osteocyte-MM cells interactions through blockade of TRPV2 channel may provide a promising treatment strategy in MM.Keywords
Funding Information
- National Natural Science Foundation of China (81372546, 81670199)
This publication has 56 references indexed in Scilit:
- Effect of TRPV2 cation channels on the proliferation, migration and invasion of 5637 bladder cancer cellsExperimental and Therapeutic Medicine, 2013
- RANKL-induced TRPV2 expression regulates osteoclastogenesis via calcium oscillationsCell Calcium, 2010
- The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive modelsNature Biotechnology, 2010
- Targeting the bone microenvironment in multiple myelomaJournal of Bone and Mineral Metabolism, 2010
- Effects of DMEM and RPMI 1640 on the biological behavior of dog periosteum-derived cellsCytotechnology, 2009
- Multiple myeloma/hypercalcemiaArthritis Research & Therapy, 2007
- Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosisBlood, 2006
- The molecular classification of multiple myelomaBlood, 2006
- Mechanisms of Bone MetastasisNew England Journal of Medicine, 2004
- Calcium signalling: dynamics, homeostasis and remodellingNature Reviews Molecular Cell Biology, 2003